Woelfle Ute, Cloos Jacqueline, Sauter Guido, Riethdorf Lutz, Jänicke Fritz, van Diest Paul, Brakenhoff Ruud, Pantel Klaus
Institute of Tumor Biology, University Hospital Hamburg-Eppendorf, Germany.
Cancer Res. 2003 Sep 15;63(18):5679-84.
Metastasis is the leading cause of cancer-related death, and bone marrow (BM) is a prominent metastatic site in solid tumors. Here, we focused on the onset of metastasis, using BM as an indicator organ for micrometastatic tumor cells in breast cancer patients without overt metastases (tumor-node-metastasis stage M(0)). Expression analysis with cDNA arrays showed distinct profiles between primary tumors from BM-positive and BM-negative patients. The differentially expressed genes are involved in extracellular matrix remodeling, adhesion, cytoskeleton plasticity, and signal transduction (in particular RAS and hypoxia-inducible factor 1alpha pathway). The BM signature was mainly characterized by transcriptional repression and different from the expression signature associated with lymphatic metastasis. Thus, BM micrometastasis is a selective process with a specific molecular signature of the primary tumor.
转移是癌症相关死亡的主要原因,而骨髓(BM)是实体瘤中一个重要的转移部位。在此,我们以骨髓作为无明显转移(肿瘤-淋巴结-转移分期M(0))的乳腺癌患者微转移肿瘤细胞的指示器官,重点研究转移的起始。利用cDNA阵列进行的表达分析显示,骨髓阳性和骨髓阴性患者的原发性肿瘤之间存在不同的表达谱。差异表达基因涉及细胞外基质重塑、黏附、细胞骨架可塑性和信号转导(特别是RAS和缺氧诱导因子1α途径)。骨髓特征主要表现为转录抑制,且不同于与淋巴转移相关的表达特征。因此,骨髓微转移是一个具有原发性肿瘤特定分子特征的选择性过程。